Without more proof of its effectiveness, Excellus is still considering the drug “investigational,” according to syracuse.com.
“Our health plan wants our members to have access to therapies that are safe, effective, and evidence-based as demonstrated by peer-reviewed clinical trials,” said Excellus Vice President Elizabeth Martin.
Aduhelm’s approval by the FDA is being reviewed by the HHS Office of Inspector General as of Aug. 4.
